A family planning clinic provides counseling for various patients with unique medical backgrounds. Match each clinical profile below with the most appropriate contraceptive method based on the standard Medical Eligibility Criteria (MEC) guidelines.
- 37-year-old patient who smokes 20 cigarettes daily and suffers from debilitating, painful menses.Levonorgestrel-eluting intrauterine system
- 24-year-old patient currently undergoing treatment for acute pelvic inflammatory disease, seeking an immediate, user-independent method.Etonogestrel subdermal implant
- 19-year-old patient experiencing unpredictable, heavy bleeding episodes secondary to anovulatory cycles.Combined oral contraceptive formulation
- 31-year-old patient taking carbamazepine for seizure management, seeking a highly reliable, non-hormonal option.Copper-bearing intrauterine system
Answer
The 37-year-old smoker matches with the levonorgestrel-eluting intrauterine system; the 24-year-old with acute pelvic inflammatory disease matches with the etonogestrel subdermal implant; the 19-year-old with anovulatory bleeding matches with the combined oral contraceptive formulation; and the 31-year-old on carbamazepine matches with the copper-bearing intrauterine system.
The correct matches strictly adhere to the standard Medical Eligibility Criteria. Patients with unacceptably high cardiovascular risks (like age over 35 combined with heavy smoking) must avoid estrogen. Patients with active pelvic inflammatory disease should not undergo intrauterine device insertion. Patients taking CYP450 inducers like carbamazepine require non-hormonal or non-systemic methods to prevent contraceptive failure. Finally, anovulatory bleeding in adolescents without contraindications is optimally managed with combined estrogen-progestin methods to stabilize the endometrium.
Step-by-Step Solution
Key Concept
Application of the Medical Eligibility Criteria (MEC) for contraceptive use across varying comorbid conditions, including cardiovascular risk factors, active pelvic infections, anovulatory bleeding, and concurrent use of hepatic enzyme-inducing medications.